ELOVL3 Antibody (V61P2B3-D10) [Janelia Fluor® 646]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-76673JF646
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human, Rat
Applications
ELISA, Immunohistochemistry
Label
Janelia Fluor 646
Antibody Source
Monoclonal Mouse IgG1 Clone # V61P2B3-D10
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Synthetic peptide of Human Elongation of very long chain fatty acids protein 3
Localization
Endoplasmic reticulum
Specificity
Detects ~40 kDa
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for ELOVL3 Antibody (V61P2B3-D10) [Janelia Fluor® 646]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein G purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: ELOVL3
Alternate Names
3-keto acyl-CoA synthase ELOVL3, CIG-30, CIG30MGC21435, Cold-inducible glycoprotein of 30 kDa, EC 2.3.1.n8, elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 3, elongation of very long chain fatty acids protein 3
Gene Symbol
ELOVL3
Additional ELOVL3 Products
Product Documents for ELOVL3 Antibody (V61P2B3-D10) [Janelia Fluor® 646]
Product Specific Notices for ELOVL3 Antibody (V61P2B3-D10) [Janelia Fluor® 646]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...